SCHEMBL38323

SCHEMBL38323

C1CNC2CCC[N]C2C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2123373 1.00
SCHEMBL1202749 0.93
SCHEMBL3420142 0.91
SCHEMBL2555322 0.89
SCHEMBL580747 0.88
SCHEMBL1383553 0.88
SCHEMBL944205 0.84
SCHEMBL332601 0.84
SCHEMBL3109256 0.77
SCHEMBL1871558 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1417 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240238425-A1 HSD17B13 Inhibitors and/or Degraders PFIZER INC. (US) 2024-07-18 US claimed
WO-2024127297-A1 3-FLUORO-4-HYDROXYBENZMIDE-CONTAINING INHIBITORS AND/OR DEGRADERS AND USES THEREOF PFIZER INC. (US) 2024-06-20 WO claimed
EP-4337639-A1 NAMPT INHIBITORS AND USES THEREOF Remedy Plan, Inc. (US) 2024-03-20 EP claimed
WO-2022241257-A1 NAMPT INHBITORS AND USES THEREOF REMEDY PLAN, INC. (US) 2022-11-17 WO claimed
US-7119098-B2 Heteroarylakanoic acids as intergrin receptor antagonists PHARMACIA CORPORATION (US) 2006-10-10 US claimed
US-12042513-B2 Proteolysis targeting chimeric molecules (PROTACs) with functional handles and uses thereof MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2024-07-23 US disclosed
US-20240239774-A1 SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF CORNELL UNIVERSITY (US) 2024-07-18 US disclosed
WO-2024151519-A2 PPARG MODULATORS UNIVERSITY OF FLORIDA RESEARCH FOUNDATIN, INCORPORATED (US) 2024-07-18 WO disclosed
US-20240238425-A1 HSD17B13 Inhibitors and/or Degraders PFIZER INC. (US) 2024-07-18 US disclosed
CN-118339152-A Macrocyclic compounds having farnesyl transferase inhibitory activity 库拉肿瘤学公司 2024-07-12 CN disclosed
US-20240228671-A1 POLYPEPTIDYL LINKERS Quantum-Si Incorporated (US) 2024-07-11 US disclosed
US-20240226302-A1 BIODEGRADABLE LIPIDS AND FORMULATIONS FOR INTRAMUSCULAR, IN VITRO, AND EX VIVO TRANSFECTION OF MRNA MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2024-07-11 US disclosed
WO-2009117808-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2009-10-01 WO disclosed
US-20090203703-A1 Thienopyrimidine Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-08-13 US disclosed
EP-2076492-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS Merck & Co., Inc. (US) 2009-07-08 EP disclosed
WO-2009076571-A1 INDOLE-SUBSTITUTED 3-CYANOPYRIDINES AS KINASE INHIBITORS WYETH (US) 2009-06-18 WO disclosed
WO-2009076602-A1 5-ALKYL/ALKENYL-3-CYANOPYRIDINES AS KINASE INHIBITORS WYETH (US) 2009-06-18 WO disclosed
WO-2008054605-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK & CO., INC. (US) 2008-05-08 WO disclosed
EP-1908765-A1 THIENOPYRIMIDINE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2008-04-09 EP disclosed
US-5280034-A Bis-heterocyclic prostaglandin analogs E. R. SQUIBB & SONS, INC. (US) 1994-01-18 US disclosed